In8Bio (INAB) Income from Continuing Operations (2020 - 2026)
In8Bio (INAB) posted Income from Continuing Operations of 5112000.0 for Q1 2026, down 5.38% sequentially from 4851000.0 in Q4 2025, and up 47.93% YoY from 3455757.06 in Q1 2025.
In8Bio (INAB) Income from Continuing Operations (2020 - 2026) Analysis & Trends
In8Bio has reported Income from Continuing Operations for 7 years, with the latest figure at 5112000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 47.93% year-over-year to 5112000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20051000.0 (up 68.58% YoY) and the FY2025 annual result came in at 46633000.0, up 15.83% from the prior year.
- Income from Continuing Operations declined to 5112000.0 in Q1 2026 per INAB's latest filing, from 4851000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 4421000.0 in Q3 2025 and troughed at 31293000.0 in Q4 2024.
- A 5-year average of 11157411.76 and a median of 8974000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 252.18% in 2022, then soared 84.5% in 2025.
- Over 5 years, Income from Continuing Operations stood at 8658000.0 in 2022, then sank by 214.65% to 27242000.0 in 2023, then decreased by 14.87% to 31293000.0 in 2024, then jumped by 84.5% to 4851000.0 in 2025, then declined by 5.38% to 5112000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 5112000.0, 4851000.0, and 4421000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | -4.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.01 Mn |
| Mar 31, 2026 | -5.11 Mn |
| Dec 31, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.42 Mn |
| Jun 30, 2025 | -5.67 Mn |
| Mar 31, 2025 | -9.82 Mn |
| Dec 31, 2024 | -31.29 Mn |
| Sep 30, 2024 | -8.38 Mn |
| Jun 30, 2024 | -14.32 Mn |
| Mar 31, 2024 | -9.90 Mn |
| Dec 31, 2023 | -27.24 Mn |
| Sep 30, 2023 | -12.10 Mn |
| Jun 30, 2023 | -9.51 Mn |
| Mar 31, 2023 | -8.97 Mn |
| Dec 31, 2022 | -8.66 Mn |
| Sep 30, 2022 | -13.47 Mn |
| Jun 30, 2022 | -7.64 Mn |
| Mar 31, 2022 | -8.32 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -5.76 Mn |